tmem263 Antibody

What is TMEM263 and why is it biologically significant?

TMEM263 is a small, highly conserved transmembrane protein (116 amino acids in humans) with two predicted transmembrane helices. It plays a critical role in regulating the growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis. Recent research has identified TMEM263 as a causal gene affecting bone mineral density (BMD) and postnatal growth through its regulation of hepatic GH receptor expression and signaling . The protein is widely expressed across tissues, with particularly high expression in the liver. Functionally, TMEM263 localizes to the plasma membrane and its absence leads to growth hormone insensitivity in mouse models .

What types of TMEM263 antibodies are currently available for research use?

Currently, researchers can access polyclonal antibodies against human TMEM263, such as the rabbit polyclonal antibody available from commercial suppliers like Atlas Antibodies (HPA042339) . These antibodies have been validated for multiple applications including immunohistochemistry (IHC), immunocytochemistry/immunofluorescence (ICC-IF), and Western blotting (WB) . The development of monoclonal antibodies against TMEM263 is still an evolving area in the field.

How is TMEM263 structurally organized and what epitopes should antibodies target?

TMEM263 is a small protein with two hydrophobic segments predicted to form transmembrane domains. The protein has been experimentally confirmed as a plasma membrane-localized protein through surface biotinylation experiments . When designing or selecting antibodies, researchers should consider epitopes in the N-terminal or C-terminal regions that are likely exposed extracellularly or intracellularly, rather than the transmembrane domains which would be inaccessible in native conformation.

How should researchers validate TMEM263 antibody specificity?

Validation of TMEM263 antibody specificity requires multiple approaches:

• Knockout/knockdown controls: Using tissues or cells from TMEM263 knockout models (as described in the mouse studies ) provides the gold standard negative control.

• Pre-adsorption tests: Incubating the antibody with a synthetic TMEM263 peptide before immunostaining can confirm specificity, as demonstrated in studies where pre-adsorption eliminated positive staining .

• Western blot analysis: Confirming detection of a ~20 kDa band (the expected size of TMEM263) in tissues known to express the protein.

• Comparison across multiple antibodies: Using antibodies targeting different epitopes of TMEM263 to verify consistent localization patterns.

• Recombinant expression systems: Overexpressing tagged TMEM263 in cell lines to confirm antibody recognition.

What are the optimal protocols for immunohistochemical detection of TMEM263?

For optimal immunohistochemical detection of TMEM263:

• Fixation: Standard formalin fixation and paraffin embedding work effectively for TMEM263 detection in tissues.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is generally recommended.

• Antibody dilution: Typically, a 1:100-1:200 dilution of commercial antibodies is effective, though optimization for specific antibodies is recommended.

• Detection systems: Both chromogenic and fluorescent detection systems can be used, with the latter providing better opportunities for co-localization studies.

• Controls: Include liver sections (highest TMEM263 expression) as positive controls and knockout tissues as negative controls when available.

How can TMEM263 subcellular localization be accurately determined?

To accurately determine TMEM263 subcellular localization:

• Surface biotinylation: As demonstrated in published research , using cell-impermeable biotinylation reagents followed by streptavidin pull-down can confirm plasma membrane localization.

• Co-localization studies: Perform double immunofluorescence with known membrane markers.

• Subcellular fractionation: Isolate membrane fractions before Western blotting.

• Immunoelectron microscopy: For high-resolution localization studies.

• Live cell imaging: Using fluorescently tagged TMEM263 constructs to monitor dynamic localization.

How can researchers investigate the role of TMEM263 in GH/IGF-1 signaling using antibody-based approaches?

Researchers can use antibody-based approaches to investigate TMEM263's role in GH/IGF-1 signaling through:

• Co-immunoprecipitation: Using TMEM263 antibodies to pull down potential interacting partners within the GH/IGF-1 pathway.

• Proximity ligation assays: To detect protein-protein interactions between TMEM263 and GH receptor or downstream signaling molecules.

• Chromatin immunoprecipitation (ChIP): To investigate whether TMEM263 participates in transcriptional regulation of GH receptor expression.

• Phospho-specific Western blotting: To examine the impact of TMEM263 manipulation on JAK2/STAT5 phosphorylation states.

• Multi-color immunofluorescence: To analyze co-localization dynamics between TMEM263 and components of the GH/IGF-1 pathway.

What considerations should be made when using TMEM263 antibodies in different species?

When using TMEM263 antibodies across species:

• Sequence homology analysis: TMEM263 is highly conserved across vertebrates, with mouse TMEM263 sharing 97% amino acid identity with human TMEM263, making cross-reactivity likely but requiring verification .

• Species validation: Always validate antibodies in the target species before performing full experiments. Western blotting with tissue lysates from the species of interest is a good starting point.

• Epitope conservation: Check whether the specific epitope recognized by the antibody is conserved in the target species using sequence alignment tools.

• Positive control tissues: Include species-appropriate positive controls (e.g., liver samples) when testing antibody performance.

• Knockout controls: When available, tissues from species-specific knockout models provide definitive negative controls.

How can researchers distinguish between different TMEM protein family members in their experiments?

To distinguish between TMEM protein family members:

• Antibody specificity testing: Test for cross-reactivity against other TMEM proteins, particularly those with sequence similarity.

• Size differentiation: TMEM263 (~20 kDa) differs in size from other TMEM proteins, such as TMEM106B which appears as a 29 kDa band in Western blots .

• Subcellular localization: Different TMEM proteins localize to different cellular compartments. For example, while TMEM263 localizes to the plasma membrane, other TMEM proteins may localize to different organelles.

• Domain-specific antibodies: Use antibodies targeting unique regions with minimal homology to other TMEM family members.

• Knockout/knockdown validation: As the gold standard approach, use genetic models lacking specific TMEM proteins to confirm antibody specificity.

What are common pitfalls when working with TMEM263 antibodies and how can they be addressed?

Common pitfalls and solutions include:

• Non-specific binding: Perform extensive blocking (3-5% BSA or serum) and include detergents (0.1-0.3% Triton X-100) in antibody diluents.

• Low signal intensity: Consider antigen retrieval optimization, signal amplification systems, or longer primary antibody incubation (overnight at 4°C).

• High background: Increase washing steps, optimize antibody concentration, and ensure tissues are properly fixed and processed.

• Inconsistent results: Standardize tissue processing protocols, antibody handling, and imaging parameters.

• Autofluorescence interference: Use Sudan Black B (0.1-0.3%) treatment to reduce autofluorescence, particularly important as TMEM263 studies often involve aged tissues with lipofuscin.

How can researchers differentiate between specific TMEM263 staining and lipofuscin autofluorescence in aged tissue samples?

Differentiating TMEM263 staining from lipofuscin autofluorescence is crucial, especially since TMEM263 studies may involve aged tissues:

• Spectral imaging: Use confocal microscopy with spectral unmixing to separate antibody-specific signals from autofluorescence.

• Autofluorescence quenching: Pre-treat sections with Sudan Black B, copper sulfate, or commercial autofluorescence quenchers.

• Multi-channel analysis: Lipofuscin autofluoresces across multiple channels, while specific antibody signals appear only in the relevant channel.

• Age-matched controls: Include appropriate age-matched controls processed without primary antibody.

• Far-red fluorophores: Use far-red secondary antibodies as lipofuscin autofluorescence is typically less intense in these wavelengths.

How should researchers interpret contradictory TMEM263 antibody results across different applications?

When faced with contradictory results:

• Application-specific validation: Some antibodies may work well for Western blotting but poorly for immunohistochemistry, or vice versa. Validate each antibody for the specific application.

• Epitope accessibility: In different applications, epitopes may be differentially accessible. For example, research has shown that antibodies targeting different epitopes of TMEM proteins can yield different results, as seen with TMEM106B where antibodies against residues 239-250 detected inclusions while antibodies against residues 263-274 did not .

• Fixation effects: Different fixation methods can affect epitope preservation differently.

• Denaturation state: Proteins in Western blots are denatured, while in IHC they may retain some native conformation.

• Confirm with multiple antibodies: Use multiple antibodies targeting different epitopes of TMEM263 to validate findings.

How can TMEM263 antibodies be used to investigate potential human growth disorders?

TMEM263 antibodies can be valuable tools for investigating human growth disorders:

• Clinical sample analysis: Examine TMEM263, GHR, and related protein expression in growth plate biopsies or liver specimens from patients with idiopathic short stature or GH insensitivity.

• Patient-derived cells: Study TMEM263 expression and localization in patient-derived fibroblasts or lymphoblasts.

• Genetic variant functional analysis: Express TMEM263 variants identified in patients in cellular models and use antibodies to assess protein stability, localization, and function.

• Tissue microarrays: Screen multiple patient samples simultaneously using TMEM263 antibodies to identify patterns of abnormal expression.

• Developmental studies: Examine TMEM263 expression patterns during different developmental stages to understand its temporal regulation.

What are the considerations for developing novel TMEM263 antibodies for specialized research applications?

For developing specialized TMEM263 antibodies:

• Novel epitope selection: Target unique, well-conserved regions of TMEM263 that are not covered by existing antibodies.

• Application-specific optimization: Design antibodies specifically for challenging applications like super-resolution microscopy or in vivo imaging.

• Phospho-specific antibodies: Develop antibodies that detect potential post-translational modifications of TMEM263.

• Intrabodies: Engineer antibodies that can function within living cells to track or modulate TMEM263 function.

• Domain-specific antibodies: Generate antibodies that can distinguish between different functional domains of TMEM263 to better understand its mechanism of action.

How might TMEM263 research inform our understanding of evolutionary adaptations in the GH/IGF-1 pathway?

TMEM263 antibodies can help explore evolutionary aspects of growth regulation:

• Cross-species analysis: Using antibodies against conserved epitopes to compare TMEM263 expression patterns across evolutionary distant vertebrates.

• Developmental timing studies: Examine how TMEM263 expression correlates with growth patterns in different species.

• Comparative analysis with other growth regulators: Study co-evolution of TMEM263 with other components of the GH/IGF-1 pathway.

• Integration with genomic data: Combine antibody-based expression studies with genomic analysis of TMEM263 conservation and selection.

• Analysis of naturally occurring variants: Study natural TMEM263 variants across species with different growth characteristics, such as the chicken dwarfism phenotype linked to TMEM263 .

How can TMEM263 antibody studies be integrated with transcriptomic and proteomic approaches?

Integration strategies include:

• Validation of expression changes: Use TMEM263 antibodies to verify protein-level changes identified in transcriptomic studies, as exemplified by studies showing widespread transcriptomic changes in Tmem263-knockout mice liver (8.6% of the liver transcriptome altered) .

• Single-cell analysis: Combine antibody-based imaging with single-cell transcriptomics to understand cellular heterogeneity in TMEM263 expression.

• Spatial transcriptomics: Correlate spatial patterns of TMEM263 protein expression with corresponding mRNA distribution.

• Proximity-based proteomics: Use TMEM263 antibodies for proximity labeling approaches like BioID or APEX to identify interaction partners.

• Post-translational modification mapping: Combine immunoprecipitation using TMEM263 antibodies with mass spectrometry to identify modifications.

What are the best approaches for studying TMEM263 function in complex tissues using antibody-based methods?

For studying TMEM263 in complex tissues:

• Multiplexed immunofluorescence: Use simultaneous staining with markers for different cell types alongside TMEM263 antibodies.

• Tissue clearing techniques: Combine TMEM263 antibodies with tissue clearing methods like CLARITY or iDISCO for 3D visualization.

• Laser capture microdissection: Use TMEM263 immunostaining to guide specific isolation of TMEM263-expressing cells for further analysis.

• In situ proximity ligation: Detect TMEM263 interactions with other proteins within the native tissue context.

• Correlative light and electron microscopy: Combine immunofluorescence with electron microscopy to study TMEM263 at ultrastructural levels.

How can researchers use TMEM263 antibodies to investigate its role in sex-specific gene expression patterns?

TMEM263 antibodies can be used to investigate sex-specific roles through:

• Comparative expression analysis: Study TMEM263 expression in male versus female tissues, particularly in liver where Tmem263 knockout has been shown to "feminize" the male liver transcriptome .

• Hormone response studies: Examine how TMEM263 expression and localization change in response to sex hormones.

• Co-immunoprecipitation: Identify sex-specific interaction partners of TMEM263.

• Chromatin studies: Investigate whether TMEM263 influences binding of sex-specific transcription factors like STAT5b.

• Developmental timing: Analyze TMEM263 expression during sexual maturation in relation to growth hormone pulsatility differences between sexes.